Dermorphin

No completed human trials extracted for Dermorphin. Animal-model evidence carries the indication cards below.

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyno dataClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice0.43.43.22.0

Measured on 4 of 6 axes

Research Evidence

Evidence shape

Dermorphin currently exists as an animal-only research peptide with no published human clinical trials. The existing literature is restricted to preclinical and mechanistic studies, providing no data on safety or efficacy in human subjects. Because there are zero registered trials and no completed human research, the clinical profile remains entirely uncharacterized.

Depthhow much
0 registered trials
Breadthhow many areas
1 indication mapped
1 animal-only
Qualityhow rigorous
No completed trials
Breadth and depth16 rows captured
Human
direct clinical signal
0
Animal
translational support
12
In vitro
mechanistic support
4
HighMediumLow

Anecdotal efficacy

Dermorphin side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

Full buying guide →
1
peptidesourcehub.com
--
50 mg
$74.90
$1.5/mg
2
HKRoids
Hong Kong
10 mg×10
$57.00
$5.7/mg
3
Bioplex Peptides
GB
5 mg
$33.54
$6.71/mg
4
Bluewell Peptides
UK
5 mg
$36.17
$7.23/mg
5
Kensington Labs
GB
5 mg
$38.79
$7.76/mg
6
Genx Peptides
US
5 mg
$45.00
$9/mg

price offers can be sorted by column · 1 out-of-stock offer not shown

Some links are affiliate links. This never affects our rankings or inclusion.

1-6 of 15

Dermorphin dosing & protocol

How Dermorphin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
—
0
500 µg
1 mg
1.5 mg
2 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
250 µg
typical
0
500 µg
1 mg
1.5 mg
2 mg
across 1 dosed source · darker = more agree
By reported cadence
Weekly250 µg · n=1
Frequency
weekly
Route
IV

Clinician practice reports a weekly intravenous dose of 250 mcg, based on a single source, and no specific cycling regimen is documented.

1 source
Anecdotal
Community-reported real-world use · n = 4
Typical dose
250 µg10 µg – 2 mg
typical
0
500 µg
1 mg
1.5 mg
2 mg
distribution of 6 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community reports list a typical dose of 250 mcg administered subcutaneously, with doses ranging from 10 mcg up to 2 mg; no consistent frequency or cycling pattern was noted.

4 sources

Related peptides

PNC-27